Love Pharma Inc. Announces Closing of Financing

Love Pharma Inc. Announces Closing of Financing

Love Pharma Inc. ("LOVE" and or "the Company") (CSE:LUV)(FSE:G1Q0), announces it has completed the second tranche of a non-brokered private placement. The Company accepted subscriptions for 2,375,000 units at a price of $0.02 per unit, for gross proceeds of $47,500. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at $0.05 for a period of two years from the date of closing, subject to the option of the Company to accelerate the expiry date in the event that its shares trade at $0.15 or more for 10 consecutive days

The Company paid $3,800 in cash and issued 190,000 broker warrants on the same terms as noted above, to qualified finders. Securities issued pursuant to this tranche are subject to trading restrictions until September 7, 2022.

Proceeds will be used for working capital and to review possible acquisitions.

About Love Pharma Inc.

With a focus on the global sexual Health and Wellness markets, Love Pharma Inc. (CSE:LUV)(FSE:G1Q0) was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

For further information, please contact:
Investor Relations
Telephone: 1 (604) 343-2977
E-mail: investors@love-pharma.com
www.love-pharma.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID-19, including the impact of COVID-19 on the Company's business, financial condition and results of operations, lack of investor demand for Bitcoin and/or Bitcoin futures exchange traded funds, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

SOURCE:Love Pharma Inc.



View source version on accesswire.com:
https://www.accesswire.com/700515/Love-Pharma-Inc-Announces-Closing-of-Financing

News Provided by ACCESSWIRE via QuoteMedia

LUV:CNX
The Conversation (0)
Love Pharma Launches Proprietary E-Commerce Platform for Online Sales

Love Pharma Launches Proprietary E-Commerce Platform for Online Sales

  • LOVE's online store launches with fully integrated e-commerce platform
  • Consumers can now purchase the Company's two proprietary branded products, BLOOM and Auralief, establishing a robust plug and play online sales presence for existing and upcoming Love Pharma products
  • The online platform seamlessly integrates social media and digital marketing capabilities for sales and marketing campaigns

Love Pharma Co. ("LOVE" and or "The Company") (CSE:LUV)(FSE:G1Q0), the Company is excited to announce the launch of the Love Pharma online shop, a fully integrated e-commerce platform featuring its proprietary products, BLOOM and Auralief, now available to purchase at https:lovepharmashop.com

"This proprietary online store will be deployed for LOVE's over-the-counter therapeutics arm, for which the Company has 6 exclusive licenses, as previously announced," said Mr. Joshua Maurice, LOVE's Chief Operating Officer. "During the initial soft-launch phase, we are focused on direct-to-consumer sales, supported by integrated social media and digital marketing campaigns. The second phase of B2B sales will build on the success of our B2C marketing and awareness strategies. We are constantly assessing results to establish the most effective B2B launch using our proprietary e-commerce platform."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Love Pharma's Investment in US Biotech Offers Strategic Industry Advantages and Enhanced Shareholder Value

Love Pharma's Investment in US Biotech Offers Strategic Industry Advantages and Enhanced Shareholder Value

Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health and sexual wellness company, remains extremely active in shaping itself into a real competitor in the biotechpharmaceutical space.  The company's growth and development plan took a major leap forward this week with the announcement that Love Pharma is establishing a "strategic alliance" with Starton Therapeutics (Starton), a leading clinical-stage biotechnology company in the United States.

It's a relationship that finds Starton ideally aligned with Love Pharma's mission of improving "quality of life" for its customers.  And the benefit to Love Pharma is that Starton is well on its way to transforming standard of care therapies with its proprietary dermal drug delivery technology that allows cancer patients to receive continuous treatment so they can live better, longer.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Love Pharma Initiates First Steps Towards a Strategic Alliance with Starton Therapeutics with Investment in this Biotech Leader

Love Pharma Initiates First Steps Towards a Strategic Alliance with Starton Therapeutics with Investment in this Biotech Leader

  • Starton Therapeutics is a leading clinical stage Biotechnology Company based in New Jersey led by CEO and Chairman, Mr. Pedro Lichtinger, Former President of Global Primary Care & President of Europe at Pfizer (PFE - NYSE)
  • Starton is focused on transforming standard of care therapies with proprietary continuous delivery technologies for selected approved drugs. The platform creates superiority regarding safety and side effect profiles over the original and can transform the drug into new indications for best-in-class oncology therapies allowing patients to live better longer lives
  • Through this initial investment, Love Pharma will be in position to imminently leverage Starton's advancements and clinical breakthroughs, helping to guide and accelerate the Company's current and prospective clinical pursuits
  • The investment establishes initial interest in Starton's ongoing growth and advancements and provides the framework to build a long-term strategic relationship

Love Pharma Co. ("LOVE" and or "The Company") (CSE:LUV)(FSE:G1Q0), the Company is pleased to announce that it has made a strategic investment in Starton Therapeutics Inc., a New Jersey based clinical stage biotechnology company focused on transforming standard of care therapies in oncology. This first investment in Starton establishes an initial position in the company and provides the starting point for a strategic relationship going forward whereby Love will leverage Starton's advancements and breakthroughs to guide the Company's clinical pursuits

"This investment provides our shareholders with exposure to a rapidly developing therapeutics business, which has just completed its phase 1 clinical trial for its STAR - LLD continuous delivery technology deploying lenalidomide (July 13 press release)," said Mr. Zach Stadnyk, Love Pharma President and CEO. "Starton is also entering a phase 2 trial with its STAR - OLZ transdermal five - day adhesive matrix patch deploying olanzapine, for which the FDA US Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for STAR-OLZ in Chemotherapy Induced Nausea and Vomiting (CINV) (press release). With this investment in Starton we are building our relationship, forming an alliance and will look to Starton's expert management team to reduce risk in our own portfolio of clinical pursuits and focus on the addiction space."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
InvestmentPitch Media Video Discusses LOVE Pharma's Shareholders' Letter from CEO Zach Stadnyk

InvestmentPitch Media Video Discusses LOVE Pharma's Shareholders' Letter from CEO Zach Stadnyk

Love Pharma (CSE:LUV) (FSE:G1Q0), an international sexual health and wellness company, has provided a shareholders' update.

Zach Stadnyk, CEO, stated: " We welcome this opportunity to provide our shareholders with a comprehensive picture of Love's efforts in building upon its existing portfolio and establishing its future strategic imperatives. Building upon LOVE's existing product portfolio, which is primarily over the counter, the Company's strategic imperative is aimed at positioning LOVE as a leader in the area of addiction treatment and recovery, within the pharmaceutical space. LOVE is actively working to identify and assess biotechnology and pharmaceutical solutions to address addiction, with intent to grow its pharmaceutical presence in underserved addiction treatment market ."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Love Pharma Delivers Letter to Shareholders

Love Pharma Delivers Letter to Shareholders

  • Love Pharma President, Mr. Zach Stadnyk, delivers comprehensive report on the Company's holdings and growth strategy
  • Building upon the Company's major research initiative, led by an addiction research leader at Johns Hopkins, its strategic focus is to identify and target pharmaceutical based addiction treatment solutions
  • Current Bloom & Auralief over the counter product line is primed for sales launch in the near term

Love Pharma Co. ("LOVE" and or "The Company") (CSE:LUV)(FSE:G1Q0), the Company is pleased to provide the following letter to shareholders, outlining the Company's advancements with key holdings and its strategy for the future

To the Shareholders of Love Pharma:

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Medicine capsule showing active ingredients.

5 Biggest Pharma Stocks in 2024

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs.

Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.

With the pharmaceutical sector projected to reach a staggering US$1.6 trillion in total revenue by 2028, there is an opportunity for investors to gain exposure to the growth potential of this industry while also benefiting from the diversification and stability provided by established companies.

Keep reading...Show less

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

- PTC to receive $1.0B in cash at closing -
  - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones -
  - PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales -
  - Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study -
  - PTC will host a conference call on Dec. 2, 2024 , at 8:30 am EST -

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE: NVS), for its PTC518 Huntington's disease program, which includes related molecules. Under the agreement, PTC will receive an upfront payment of $1.0 billion up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Ratio to receive upfront, and potential milestones and tiered royalty payments

Ratio Therapeutics Inc. ( Ratio ), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS). The collaboration leverages Ratio's radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2024

The global pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Pill spelling "big pharma."

Big Pharma Stocks Eli Lilly, AbbVie and Pfizer Share Q3 Results

Major pharmaceutical players Eli Lilly (NYSE:LLY), AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) reported mixed Q3 results, with each company facing distinct market forces, ranging from supply issues to financial constraints.

In its latest quarterly report, released on Wednesday (October 30), Eli Lilly missed on sales expectations for Zepbound, its popular weight-loss drug, and Mounjaro, its diabetes medication. Despite growing US demand for these products, supply chain management issues impacted the company’s ability to meet Wall Street's expectations.

According to Reuters, Eli Lilly dropped 8 percent on the news, reducing its market valuation by nearly US$70 billion.

Keep reading...Show less
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

4 Best-performing Canadian Pharma Stocks of 2024

From established players to up-and-coming firms, Canada's pharmaceutical company is diverse and dynamic.

Canadian pharma companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.

Here the Investing News Network lists the top Canadian pharma stocks on the TSX, TSXV and CSE by year-to-date gains. All data was compiled on October 28, 2024, using TradingView’s stock screener, and the companies considered had market caps above C$10 million at that time. Read on to learn about what's been driving their share prices.

Keep reading...Show less

Latest Press Releases

Related News

×